Full Guidelines-From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis

By sjmartinez • July 22, 2024

James WA, Rosenberg AL, Wu JJ, Hsu S, Armstrong A, Wallace EB, Lee LW, Merola J, Schwartzman S, Gladman D, Liu C, Koo J, Hawkes JE, Reddy S, Prussick R, Yamauchi P, Lewitt M, Soung J, Weinberg J, Lebwohl M, Glick B, Kircik L, Desai S, Feldman SR, Zaino ML. Full Guidelines-From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2024 Aug;91(2):251.e1-251.e11. doi: 10.1016/j.jaad.2024.03.008. Epub 2024 Mar 17. PMID: 38499181.

Tags: abatacept, acitretin, apremilast, biologic, cyclosporine, Dermatology, IL-12/23 inhibitor, IL-17 inhibitor, IL-23 inhibitor, immunosuppressant, methotrexate, Perioperative, psoriasis, psoriatic arthritis, Publications, tofacitinib, tumor necrosis factor-alfa inhibitors

Related Posts

Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials

Thaçi D, Puig L, Motegi SI, Papp K, Stein Gold L, Kircik L, Sofen H, Fernández-Peñas P, Herranz P, Vestergaard C, Huang YH, Dossenbach M,[...]

Global Healthcare Study on Psoriasis (GHSP): cohort profile and first findings

Maul JT, Fröhlich F, Nielsen ML, Maul LV, Torres T, Thyssen J, Armstrong A, Oon HH, Ji M, Kang X, Valenzuela F, Romiti R, Carvalho[...]

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial

Elbuluk N, Armstrong AW, Vender R, Bhutani T, Green L, Ferris LK, Laquer V, Moore A, Weisman J, Zhang W, Winkelman W, Gooderham MJ. Zasocitinib[...]